Table 1.
Demographic and clinical characteristics of patients with obesity and matched controls: Crohn's disease.
| Crohn's disease (BMI > 30) | Crohn's disease (BMI < 30) | P-value | |
|---|---|---|---|
| No. of patients | 16 | 64 | |
| Median BMI at diagnosis (range) | 31.8 (30.1–41.5) | 19.1 (14.5–29.3) | |
| Male (%) | 11 (68.8) | 44 (68.8) | 1.000 |
| Median age at diagnosis (range), year | 21.3 (17.9–34.8) | 21.2 (17.9–35.9) | 0.957 |
| Median interval from onset to diagnosis (range), months | 9.4 (0.0–117.7) | 9.5 (0.1–108.2) | 0.995 |
| Mean follow-up after diagnosis of IBD (months) | 102.1 ± 58.4 | 91.0 ± 48.6 | 0.435 |
| Smoking status at diagnosis (%) | 0.517 | ||
| Current smokers | 5 (31.3) | 20 (31.3) | |
| Ex-smokers | 1 (6.3) | 1 (1.6) | |
| Never-smokers | 10 (62.5) | 43 (67.2) | |
| Disease location at diagnosis (Montreal classification) | 0.712 | ||
| L1 (terminal ileum) | 5 (31.3) | 14 (21.9) | |
| L2 (colon) | 1 (6.3) | 4 (6.3) | |
| L3 (ileocolon) | 10 (62.5) | 46 (71.9) | |
| L4 (upper GI modifier) | 4 (25.0) | 16 (25.0) | 1.000 |
| Disease location, final (Montreal classification) | 1.000 | ||
| L1 (terminal ileum) | 4 (25.0) | 14 (21.9) | |
| L2 (colon) | 0 (0.0) | 3 (4.7) | |
| L3 (ileocolon) | 12 (75.0) | 47 (73.4) | |
| L4 (upper GI modifier) | 4 (25.0) | 18 (28.1) | 1.000 |
| Perianal fistula | 0.592 | ||
| At diagnosis | 8 (50.0) | 24 (37.5) | |
| Occurrence during follow-up | 1 (6.3) | 8 (12.5) | |
| Never | 7 (43.8) | 32 (50.0) | |
| Disease behavior at diagnosis (Montreal classification) | 1.000 | ||
| B1 (nonstricturing and nonpenetrating) | 13 (81.3) | 48 (75.0) | |
| B2 (stricturing) | 1 (6.25) | 5 (7.8) | |
| B3 (penetrating) | 2 (12.5) | 11 (17.2) | |
| Disease behavior, final (Montreal classification) | 0.717 | ||
| B1 (nonstricturing and nonpenetrating) | 9 (56.3) | 41 (64.1) | |
| B2 (stricturing) | 2 (12.5) | 10 (15.6) | |
| B3 (penetrating) | 5 (31.3) | 13 (20.3) | |
| Medication history | |||
| Steroids | 7 (43.8) | 37 (57.8) | 0.334 |
| Immunomodulators | 16 (100.0) | 57 (89.1) | 0.312 |
| Anti-tumor necrosis factor therapy | 8 (50.0) | 21 (32.8) | 0.201 |
| Surgical outcomes | |||
| Bowel resection | 7 (43.8) | 18 (28.1) | 0.228 |
GI, gastrointestinal, IBD, inflammatory bowel disease, UC, ulcerative colitis, and BMI, body mass index.